Literature DB >> 11514473

Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease.

J S Sidhu1, J C Kaski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11514473      PMCID： PMC1729884          DOI： 10.1136/heart.86.3.255

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  44 in total

Review 1.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

2.  Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.

Authors:  I Barroso; M Gurnell; V E Crowley; M Agostini; J W Schwabe; M A Soos; G L Maslen; T D Williams; H Lewis; A J Schafer; V K Chatterjee; S O'Rahilly
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

3.  Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells.

Authors:  S Goetze; X P Xi; K Graf; E Fleck; W A Hsueh; R E Law
Journal:  FEBS Lett       Date:  1999-06-11       Impact factor: 4.124

Review 4.  Prevention of coronary restenosis.

Authors:  P J Casterella; P S Teirstein
Journal:  Cardiol Rev       Date:  1999 Jul-Aug       Impact factor: 2.644

5.  Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

Authors:  K Kato; H Satoh; Y Endo; D Yamada; S Midorikawa; W Sato; K Mizuno; T Fujita; K Tsukamoto; T Watanabe
Journal:  Biochem Biophys Res Commun       Date:  1999-05-10       Impact factor: 3.575

6.  Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells.

Authors:  K Murao; H Imachi; A Momoi; Y Sayo; H Hosokawa; M Sato; T Ishida; J Takahara
Journal:  FEBS Lett       Date:  1999-07-02       Impact factor: 4.124

Review 7.  Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?

Authors:  G Christ; K Kostner; M Zehetgruber; B R Binder; D Gulba; K Huber
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

8.  Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance.

Authors:  S Sunayama; Y Watanabe; H Ohmura; M Sawano; K Shimada; H Mokuno; H Daida; H Yamaguchi
Journal:  Atherosclerosis       Date:  1999-09       Impact factor: 5.162

9.  Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells.

Authors:  M Asano; T Nakajima; K Iwasawa; T Morita; F Nakamura; H Imuta; K Chisaki; N Yamada; M Omata; Y Okuda
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

10.  Restenosis after percutaneous transluminal coronary angioplasty in patients with non-insulin-dependent diabetes mellitus (NIDDM).

Authors:  Y Asakura; M Suzuki; H Nonogi; K Haze; A Sato; H Inada; Y Okuda; K Yamashita; Y Harano
Journal:  J Cardiovasc Risk       Date:  1998 Oct-Dec
View more
  3 in total

1.  Cardioprotective effects of peroxisome proliferator activated receptor gamma activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor kappaB blockade.

Authors:  Z Yuan; Y Liu; Y Liu; J Zhang; C Kishimoto; Y Wang; A Ma; Z Liu
Journal:  Heart       Date:  2005-03-17       Impact factor: 5.994

2.  Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction.

Authors:  Stefan Frantz; Kai Hu; Julian Widder; Barbara Bayer; Catharina Clara Witzel; Isabel Schmidt; Paolo Galuppo; Jörg Strotmann; Georg Ertl; Johann Bauersachs
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

Review 3.  Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

Authors:  Michaela Diamant; Robert J Heine
Journal:  Drugs       Date:  2003       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.